NAPOLI-3: NALIRIFOX Versus Nab-Paclitaxel + Gemcitabine for Metastatic Pancreatic Ductal Adenocarcinoma

Zev Wainberg, MD, MSc, University of California, Los Angeles, provides insight on the NAPOLI-3 study that compared the safety and efficacy of NALIRIFOX (liposomal irinotecan, oxaliplatin, leucovorin, and fluorouracil) against nab-paclitaxel plus gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma.

Dr. Wainberg discusses the differences between the OS and PFS rates of the two treatments, as well as ongoing studies examining other treatments that may work in tandem with NALIRIFOX.